Type 2 diabetes mellitus and hypertension: An update

Endocrinology and Metabolism Clinics of North America

Volumn 43, Issue 1, 2014, Pages 103-122

  Lastra, Guido ^a,b,c   Syed, Sofia ^a,b   Kurukulasuriya, L Romayne ^a   Manrique, Camila ^a,b,c   Sowers, James R ^a,b,c  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Chronic kidney disease; Diabetes; Hypertension; Renin angiotensin aldosterone system; Sympathetic nervous system

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; RENIN INHIBITOR;

ADAPTIVE IMMUNITY; ADRENERGIC STIMULATION; BLOOD PRESSURE REGULATION; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID BODY DENERVATION; CHRONIC KIDNEY DISEASE; COMORBIDITY; DENERVATION; DEPRESSION; DIABETOGENESIS; DRUG MEGADOSE; DRUG TOLERABILITY; FAINTNESS; HIGH RISK PATIENT; HUMAN; HYPERINSULINEMIA; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY DENERVATION; KIDNEY DYSFUNCTION; LIFESTYLE MODIFICATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RESTRICTION; TELEHEALTH; VASODILATATION; DIABETES MELLITUS, TYPE 2; METABOLISM;

COMORBIDITY; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION;

EID: 84896731158     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2013.09.005     Document Type: Review

References (123)

1. Sowers J.R., Epstein M., Frohlich E.D. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001, 37:1053-1059.
2. Sowers J.R., Whaley-Connell A., Hayden M. The role of overweight and obesity in the cardiorenal syndrome. Cardiorenal Med 2011, 1:5-12.
3. Sowers J.R. Diabetes mellitus and vascular disease. Hypertension 2013, 61(5):943-947.
4. Stamler J., Vaccaro O., Neaton J.D., et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
5. Hu G., Jousilahti P., Tuomilehto J. Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. Eur Heart J 2007, 28:3059-3066.
6. Sarwar N., Gao P., Seshasai S.R., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222. Emerging Risk Factors Collaboration.
7. Fox C.S. Cardiovascular disease risk factors, type 2 diabetes mellitus, and the Framingham Heart Study. Trends Cardiovasc Med 2010, 20:90-95.
8. Chen G., McAlister F.A., Walker R.L., et al. Cardiovascular outcomes in Framingham participants with diabetes: the importance of blood pressure. Hypertension 2011, 57:891-897.
9. Egan B.M., Zhao Y., Axon R.N. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010, 303:2043.
10. Wright J.D., Hughes J.P., Ostchega Y., et al. Mean systolic and diastolic blood pressure in adults aged 18 and over in the United States, 2001-2008. Natl Health Stat Report 2011, 35:1-22. 24.
11. Kaplan N.M., Victor R.G. Hypertension in the population at large. Kaplan's clinical hypertension 2010, 1. Wolter's Kluwer, Philadelphia. 10th edition. N.M. Kaplan, R.G. Victor (Eds.).
12. Green A.J., Bazata D.D., Fox K.M., et al. Quality of life, depression, and healthcare resource utilization among adults with type 2 diabetes mellitus and concomitant hypertension and obesity: a prospective survey. Cardiol Res Pract 2012, 10.1155/2012/404107.
13. Eaddy M.T., Shah M., Lunacsek O., et al. The burden of illness of hypertension and comorbid diabetes. Curr Med Res Opin 2008, 24:2501-2507.
14. Haffner S.M., Valdez R., Morales P.A., et al. Greater effect of glycemia on incidence of hypertension in women than in men. Diabetes Care 1992, 15:1277-1284.
15. Hu G., DECODE Study Group Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia 2003, 46:608-617.
16. Carson A.P., Howard G., Burke G.L., et al. Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis. Hypertension 2011, 57:1101-1107.
17. Dyer A.R., Liu K., Walsh M., et al. Ten-year incidence of elevated blood pressure and its predictors: the CARDIA Study, Coronary Artery Risk Development in (Young) Adults. JHum Hypertens 1999, 13:13-21.
18. Etkin N., Mahoney J., Forsthoefel M., et al. Racial differences in hypertension-associated red cell sodium permeability. Nature 1982, 297:588-589.
19. Liu X., Song P. Is the association of diabetes with uncontrolled blood pressure stronger in Mexican Americans and Blacks than in Whites among diagnosed hypertensive patients?. Am J Hypertens 2013, [Epub ahead of print].
20. Ogden C.L., Carroll M.D., Kit B.K., et al. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012, 307:483-490.
21. TODAY Study Group Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care 2013, 36:1735-1741.
22. Massiera F., Bloch-Faure M., Ceiler D., et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001, 15:2727-2729.
23. Boustany C.M., Bharadwaj K., Daugherty A., et al. Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol 2004, 287:R943-R949.
24. Mehta P.K., Griendling K.K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007, 292:C82-C97.
25. Williams J.S., Williams G.H. 50th anniversary of aldosterone. JClin Endocrinol Metab 2003, 88:2364-2372.
26. Whaley-Connell A., Johnson M.S., Sowers J.R. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis 2010, 52:401-409.
27. Caprio M., Feve B., Claes A., et al. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007, 21:2185-2194.
28. Jeon J.H., Kim K.Y., Kim J.H., et al. Anovel adipokine CTRP1 stimulates aldosterone production. FASEB J 2008, 22:1502-1511.
29. Cooper S.A., Whaley-Connell A., Habibi J., et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007, 293:H2009-H2023.
30. Taniyama Y., Griendling K.K. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003, 42:1075-1081.
31. Madamanchi N.R., Vendrov A., Runge M.S. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005, 25:29-38.
32. Dröge W. Free radicals in the physiological control of cell function. Physiol Rev 2002, 82:47-95.
33. Johar S., Cave A.C., Narayanapanicker A., et al. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 2006, 20:1546-1548.
34. Barhoumi T., Kasal D.A., Li M.W., et al. Tregulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 2011, 57:469-476.
35. Brown N.J. Aldosterone and vascular inflammation. Hypertension 2008, 51:161-167.
36. Ferrannini E., Buzzigoli G., Bonadonna R., et al. Insulin resistance in essential hypertension. NEngl J Med 1987, 317:350-357.
37. Bonora E., Capaldo B., Perin P.C., et al. Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. Nutr Metab Cardiovasc Dis 2008, 18:624-631.
38. Muniyappa R., Quon M.J. Insulin action and insulin resistance in vascular endothelium. Curr Opin Clin Nutr Metab Care 2007, 10:523-530.
39. Vincent M.A., Montagnani M., Quon M.J. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. Curr Diab Rep 2003, 3:279-288.
40. Taniguchi C.M., Emanuelli B., Kahn C.R. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006, 7:85-96.
41. Potenza M.A., Marasciulo F.L., Chieppa D.M., et al. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol 2005, 289:H813-H822.
42. Formoso G., Chen H., Kim J.A., et al. Dehydroepiandrosterone mimics acute actions of insulin to stimulate production of both nitric oxide and endothelin 1via distinct phosphatidylinositol 3-kinase- and mitogen-activated protein kinase-dependent pathways in vascular endothelium. Mol Endocrinol 2006, 20:1153-1163.
43. Mukai Y., Wang C.Y., Rikitake Y., et al. Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type-1 expression in vascular endothelial cells. Am J Physiol Heart Circ Physiol 2006, 292:H1937-H1942.
44. Kim J., Montagnani M., Kwaug K.K., et al. Reciprocal relationship between insulin resistance and endothelial dysfunction. Circulation 2006, 113:1888-1904.
45. Heagerty A.M., Heerkens E.H., Izzard A.S. Small artery structure and function in hypertension. JCell Mol Med 2010, 14:1037-1043.
46. Anderson E.A., Hoffman R.P., Balon T.W., et al. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. JClin Invest 1991, 87:2246-2252.
47. Landsberg L. Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). JHypertens 2001, 19:523-528.
48. Haynes W.G., Morgan D.A., Walsh S.A., et al. Receptor-mediated regional sympathetic nerve activation by leptin. JClin Invest 1997, 100:270-278.
49. Song J., Hu X., Riazi S., et al. Regulation of blood pressure, the epithelial sodium channel (ENaC), and other key renal sodium transporters by chronic insulin infusion in rats. Am J Physiol Renal Physiol 2006, 290:F1055-F1064.
50. Tiwari S., Sharma N., Gill P.S., et al. Impaired sodium excretion and increased blood pressure in mice with targeted deletion of renal epithelial insulin receptor. Proc Natl Acad Sci USA 2008, 105:6469-6774.
51. Muscelli E., Natali A., Bianchi S., et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 1996, 9:746-752.
52. Garcia-Touza M., Sowers J.R. Evidence-based hypertension treatment in patients with diabetes. JClin Hypertens (Greenwich) 2012, 14:97-102.
53. Cushman W.C., Evans G.W., Byington R.P., ACCORD Study Group, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. NEngl J Med 2010, 362:1575-1585.
54. American Diabetes Association Standards of medical care in diabetes-2011. Diabetes Care 2011, 34:S11-S61.
55. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713.
56. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755-1762.
57. Tuomilehto J., Rastenyte D., Birkenhäger W.H., et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. NEngl J Med 1999, 340:677-684.
58. Curb J.D., Pressel S.L., Cutler J.A., et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996, 276:1886-1892.
59. Schrier R.W., Estacio R.O., Jeffers B. Appropriate blood pressure control in NIDDM (ABCD) trial. Diabetologia 1996, 39:1646-1654.
60. Cooper-DeHoff R.M., Gong Y., Handberg E.M., et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010, 304:61-68.
61. American Diabetes Association Standards of medical care in diabetes-2013. Diabetes Care 2013, 36:S11-S66.
62. Redon J., Mancia G., Sleight P., ONTARGET Investigators, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). JAm Coll Cardiol 2012, 59:74-83.
63. Bangalore S., Kumar S., Lobach I., et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation 2011, 123:2799-2810.
64. Kim Y.S., Davis S.C., Truijen J., et al. Intensive blood pressure control affects cerebral blood flow in type 2 diabetes mellitus patients. Hypertension 2011, 57:738-745.
65. Cummings D.M., Letter A.J., Howard G., et al. Generic medications and blood pressure control in diabetic hypertensive subjects: results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Diabetes Care 2013, 36:591-597.
66. Tuomilehto J., Lindström J., Eriksson J.G., Finnish Diabetes Prevention Study Group, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. NEngl J Med 2001, 344:1343-1350.
67. Sacks F.M., Svetky L.P., Vollmer W.M., et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. NEngl J Med 2001, 344:3-10.
68. Azadbakht L., Fard N.R., Karimi M., et al. Effects of the dietary approaches to stop hypertension (DASH) eating plan on cardiovascular risks among type 2 diabetic patients. Diabetes Care 2011, 34:55-57.
69. Azadbakht L., Surkan P.J., Esmaillzadeh A., et al. The dietary approaches to stop hypertension eating plan affects C-reactive protein, coagulation abnormalities, and hepatic function tests among type 2 diabetic patients. JNutr 2011, 141:1083-1088.
70. Noda K., Zhang B., Iwata A., STYLIST Study Investigators, et al. Lifestyle changes through the use of delivered meals and dietary counseling in a single-blind study. The STYLIST study. Circ J 2012, 76:1335-1344.
71. Cook N.R., Cutler J.A., Obarzanek E., et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007, 334:885-888.
72. Cook N.R., Kumanyika S.K., Cutler J.A. Effect of change in sodium excretion on change in blood pressure corrected for measurement error. The Trials of Hypertension Prevention, Phase I. Am J Epidemiol 1998, 148:431-444.
73. Taylor R.S., Ashton K.E., Moxham T., et al. Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane Review). Am J Hypertens 2011, 24:843-853.
74. Rugale C., Oudot C., Desmetz C., et al. Sodium restriction prevents cardiovascular remodeling associated with insulin-resistance in the rat. Ann Cardiol Angeiol (Paris) 2013, 62:139-143.
75. Whelton S.P., Chin A., Xin X., et al. Effect of aerobic exercise on blood pressure: a metaanalysis of randomized, controlled trials. Ann Intern Med 2002, 136:493-503.
76. Hansson L., Lindholm L.H., Niskanen L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999, 353:611-616.
77. ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
78. The Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. NEngl J Med 2000, 342:145-153.
79. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253-259.
80. Lindholm L.H., Ibsen H., Dahlöf B., LIFE Study Group, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004-1010.
81. Ogihara T., Nakao K., Fukui T., Candesartan Antihypertensive Survival Evaluation in Japan Trial Group, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan Trial. Hypertension 2008, 51:393-398.
82. Fretheim A. VALUE: analysis of results. Lancet 2004, 364:934-935.
83. Yusuf S., Teo K.K., Pogue J., ONTARGET Investigators, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. NEngl J Med 2008, 358:1547-1559.
84. Ruggenenti P., Perna A., Ganeva M., et al. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. JAm Soc Nephrol 2006, 17:3472-3481.
85. Haller H., Ito S., Izzo J., et al. Olmesartan for delay or prevention of microalbuminuria in type 2 diabetes. NEngl J Med 2011, 364:907-917.
86. Bilous R., Chatuverdi N., Sjolie A.K., et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009, 5:11-20.
87. Lastra G., Whaley-Connell A., Manrique C., et al. Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab 2008, 295:E110-E116.
88. Lastra-Lastra G., Sowers J.R., Restrepo-Erazo K., et al. Role of aldosterone and angiotensin II in insulin resistance: an update. Clin Endocrinol 2009, 71:1-6.
89. Estacio R.O., Jeffers B.W., Hiatt W.R., et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. NEngl J Med 1998, 338:645-652.
90. Tatti P., Pahor M., Byington R.P., et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998, 21:597-603.
91. Leenen F.H., Nwachuku C.E., Black H.R., Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack trial. Hypertension 2006, 48:374-384.
92. Julius S., Kjeldsen S.E., Weber M., VALUE Trial Group, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022-2031.
93. Berl T., Hunsicker L.G., Lewis J.B., Irbesartan Diabetic Nephropathy Trial, Collaborative Study Group, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003, 138:542-549.
94. Ostergren J., Poulter N.R., Sever P.S., ASCOT Investigators, et al. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. JHypertens 2008, 26:2103-2111.
95. Beckett N.S., Peters R., Fletcher A.E., HYVET Study Group, et al. Treatment of hypertension in patients 80 years of age or older. NEngl J Med 2008, 358:1887-1898.
96. Manrique C., Johnson M., Sowers J.R. Thiazide diuretics alone or with beta-blockers impair glucose metabolism in hypertensive patients with abdominal obesity. Hypertension 2010, 55:15-17.
97. Cooper-DeHoff R.M., Wen S., Beitelshees A.L., et al. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension 2010, 55:61-68.
98. Raheja P., Price A., Wang Z., et al. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension 2012, 60:319-325.
99. Zhou X., Ma L., Habibi J., et al. Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension 2010, 55:880-888.
100. Campbell J.E., Drucker D.J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013, 17:819-837.
101. Thorens B., Porret A., Buhler L., et al. Cloning and functional expression of the human islet GLP-1 receptor: demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993, 42:1678-1682.
102. Gros R., You X., Baggio L.L., et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003, 144:2242-2252.
103. Grieve D.J., Cassidy R.S., Green B.D. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?. Br J Pharmacol 2009, 157:1340-1351.
104. Ussher J.R., Drucker D.J. Cardiovascular biology of the incretin system. Endocr Rev 2012, 33:187-215.
105. Horton E.S., Silberman C., Davis K.L., et al. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care 2010, 33:1759-1765.
106. Mistry G.C., Maes A.L., Lasseter K.C. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. JClin Pharmacol 2008, 48:592-598.
107. Aroor A.R., Sowers J.R., Bender S.B., et al. Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats. Endocrinology 2013, 154:2501-2513.
108. Liu L., Liu J., Wong W.T., et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 2012, 60:833-841.
109. Ossum A., van Deurs U., Engstrøm T., et al. The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart. Pharmacol Res 2009, 60:411-417.
110. Girardi A.C., Fukuda L.E., Rossoni L.V., et al. Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule. Am J Physiol Renal Physiol 2008, 294:F414-F422.
111. Pacheco B.P., Crajoinas R.O., Couto G.K., et al. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. JHypertens 2011, 29:520-528.
112. Sharma A.M., Bakris G., Neutel J.M., et al. Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial. Clin Ther 2012, 34:537-551.
113. Weber M.A., Bakris G.L., Jamerson K., ACCOMPLISH Investigators, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. JAm Coll Cardiol 2010, 56:77-85.
114. Dahlof B., Swever P.S., Poulter N.R., ASCOT Investigators, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA); a multicenter randomised controlled trial. Lancet 2005, 366:895-906.
115. Gupta A.K., Arshad S., Poulter N.R. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010, 55:399-407.
116. Chrysant S.G., Littlejohn T., Izzo J.L., et al. Triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study. Am J Cardiovasc Drugs 2012, 12:233-243.
117. Wakefield B.J., Holman J.E., Ray A., et al. Effectiveness of home telehealth in comorbid diabetes and hypertension: a randomized, controlled trial. Telemed J E Health 2011, 17:254-261.
118. Johns E.J., Abdulla M.H. Renal nerves in blood pressure regulation. Curr Opin Nephrol Hypertens 2013, 22:504-510.
119. Symplicity HTN-2 Investigators, Esler M.D., Krum H., et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010, 376:1903-1909.
120. Mahfoud F., Schlaich M., Kindermann I., et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011, 123:1940-1946.
121. Mahfoud F., Ukena C., Schmieder R.E., et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 2013, 128:132-140.
122. Fagard R.H., Celis H., Thijs L., et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 2008, 51:55.
123. Pickering T.G., Shimbo D., Haas D. Ambulatory blood-pressure monitoring. NEngl J Med 2006, 354:2368-2374.